Drug Search Results
More Filters [+]

Bemarituzumab

Alternative Names: bemarituzumab, fpa-144, fpa144, fpa 144, amg 552, amg-552, amg552
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Bemarituzumab is currently being evaluated in combination with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing advanced-stage GEA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32167861/)

Mechanisms of Action: FGFR2 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: Breakthrough Therapy - Gastrointestinal Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bemarituzumab

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 21

Highest Development Phases

Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

Phase 2: Cervical Cancer|Cholangiocarcinoma|Endometrial Cancer|Head and Neck Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer

Phase 1: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-512484-31-00

P2

Unknown Status

Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2028-03-31

BEMARA

P2

Not yet recruiting

Adenocarcinoma|Esophageal Cancer

2027-09-01

jRCT2031210669

P3

Recruiting

Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2027-01-26

20210098

P3

Unknown Status

Gastrointestinal Cancer|Esophageal Cancer

2027-01-04

Recent News Events